All Posts By

Smartkarma Daily Briefs

Daily Brief India: Brightcom Group, Zen Technologies and more

By | Daily Briefs, India

In today’s briefing:

  • Indian Forensic Playbook: Guidelines to Identify and Avoid Storified Stocks
  • Zen Technologies: Building a Strong Moat in Indian Defence Theme


Indian Forensic Playbook: Guidelines to Identify and Avoid Storified Stocks

By Nimish Maheshwari

  • Indian SMEs are new hot investment avenues selling stories to investors which might end to a case of pump and dump.
  • SEBI in last few months have identified such cases in SMEs and microcaps.
  • We delved into key guidelines on Indian Forensics to Identify and Avoid Storified Stocks

Zen Technologies: Building a Strong Moat in Indian Defence Theme

By Sudarshan Bhandari

  • Zen Technologies (ZEN IN) expands product range to drones, anti-drone systems, and medical simulators, enhancing opportunities beyond government contracts.
  • Strong order book of Rs 1,401 crore, significant R&D investment, and government support for indigenous defence manufacturing drive growth.
  • Zen Technologies (ZEN IN) diversified product portfolio and strategic government support position it well for significant growth in the defence and simulation markets.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Japan Post Holdings, Dentsu Inc and more

By | Daily Briefs, Japan

In today’s briefing:

  • Last Week in Event SPACE: Japan Post, Great Eastern, Malaysia Airports, L’Occitane
  • Dentsu Group – FY24 prospects weighted to H2


Last Week in Event SPACE: Japan Post, Great Eastern, Malaysia Airports, L’Occitane

By David Blennerhassett


Dentsu Group – FY24 prospects weighted to H2

By Edison Investment Research

Dentsu’s Q1 results indicate a slow start to the year, with organic net revenue down by 3.7%. However, prospects are improving, buoyed by new business wins and weighted to H2, which leave full year expectations (and our forecasts) unchanged. The One dentsu initiative, bringing together skill sets in consulting, technology, media and creative, is supporting improved pitch win rates, and giving greater coherence and consistency to the group product and service offering. We expect this to be a central element of the new management medium-term strategy, set to be unveiled during H2. The rating remains at a substantial discount to global peers, which we anticipate will narrow as evidence of renewed growth builds.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: ESR Group , Li Auto , Yichang HEC Changjiang Pharma, BYD Electronics, Tencent, KraneShares CSI China Internet ETF, Zijin Mining Group Co Ltd H and more

By | China, Daily Briefs

In today’s briefing:

  • (Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market
  • HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way
  • Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid
  • HSI June 2024 Rebal – BYD Electronics (285) ADDed, Cogard Svcs (6098) DELETEd, and Capping Flows
  • A Few Generative AI Takeaways From C1Q24 Earnings
  • Red Dragon Awakening
  • HSCEI June 2024 Rebal – Zijin Mining (2899) ADDed, Xinyi Solar (968) DELETEd


(Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market

By David Blennerhassett


HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way

By Travis Lundy

  • The Hang Seng Tech Index is more widely-followed than many think, and it is reasonably concentrated, so outperformance and underperformance by big names means capping and re-capping.
  • This time, those flows are worth about 8% of the index in terms of one-way flows. Meituan, Xiaomi, JD.com, Tencent and Kuaishou Tech DOWN. Li Auto back up. 
  • Those who have pre-positioned on the big buy have recently gotten hurt. There are some FAF changes which are less predictable and may be interesting.

Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid

By David Blennerhassett

  • A “Privatisation via a Merger by Absorption” is nothing new in Hong Kong. But the Offer consideration for Yichang HEC (1558 HK)‘s minorities is in unlisted scrip – that’s new. 
  • The Offeror holds 51.41% in Yichang HEC. Founder Guo Meilan and her son Zhang Yushuai control 62.12% of the Offeror. Yichang HEC shareholders are being offered 0.263614 “Offeror H shares”.
  • These consideration shares are unlisted. An independent valuer backs out an implied scrip value of HK$18.12-HK$20.60/share. This is a super complicated, overwrought deal. With numerous unknowns. I’d vote this down. 

HSI June 2024 Rebal – BYD Electronics (285) ADDed, Cogard Svcs (6098) DELETEd, and Capping Flows

By Travis Lundy

  • The Hang Seng Index benchmark has been expected to see an increase in names and flows to Healthcare. We have only one ADD (IT/tech) and one DELETE.
  • But the headlined DELETE candidate in the most recent Quiddity Leaderboard was chosen to be deleted. And the ADD one of our top two.
  • Flows are somewhat restrained at capping flows, small name change flows, and then a few FFW/FAF changes to be about 1.9% one-way flows in total.

A Few Generative AI Takeaways From C1Q24 Earnings

By Eric Wen

  • The key takeaway from this earning season on the topic of generative AI (GAI) is that in-house generated content has the greatest potential for cost savings;
  • Taking a step further, mid-sized video platforms can also use AI to skip the curator layer, similar to Pinduoduo using algorithm to bypass small merchants to connect directly to factories;
  • We also notice that general media platforms with ample advertising inventories tend to perform better with AI’s help, which is why ads of Tencent’s advertising performed better than Baidu’s.

Red Dragon Awakening

By Douglas Busch

  • China momentum continues with KWEB breaking out above WEEKLY double-bottom base
  • Stocks REPORTING this week that look technically sound include PDD BZ and EH
  • In-Depth look at individual leaders in Tencent Holdings, Futu Holdings, and Sony Group

HSCEI June 2024 Rebal – Zijin Mining (2899) ADDed, Xinyi Solar (968) DELETEd

By Travis Lundy

  • The HSCEI is well-known and well-followed but sees less passive tracking than you might expect. Quiddity teammember Janaghan had expected up to two ADDs and two DELETEs.
  • We got one ADD and one DELETE instead as SenseTime Group (20 HK) was “saved” from deletion by a FFW/FAF increase. 
  • Relatively smaller flows here at 3% one-way with the big flows on the name changes.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Zen Technologies, Japan Post Holdings and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Zen Technologies: Building a Strong Moat in Indian Defence Theme
  • Last Week in Event SPACE: Japan Post, Great Eastern, Malaysia Airports, L’Occitane


Zen Technologies: Building a Strong Moat in Indian Defence Theme

By Sudarshan Bhandari

  • Zen Technologies (ZEN IN) expands product range to drones, anti-drone systems, and medical simulators, enhancing opportunities beyond government contracts.
  • Strong order book of Rs 1,401 crore, significant R&D investment, and government support for indigenous defence manufacturing drive growth.
  • Zen Technologies (ZEN IN) diversified product portfolio and strategic government support position it well for significant growth in the defence and simulation markets.

Last Week in Event SPACE: Japan Post, Great Eastern, Malaysia Airports, L’Occitane

By David Blennerhassett


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Energy/Materials: Zijin Mining Group Co Ltd H and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • HSCEI June 2024 Rebal – Zijin Mining (2899) ADDed, Xinyi Solar (968) DELETEd


HSCEI June 2024 Rebal – Zijin Mining (2899) ADDed, Xinyi Solar (968) DELETEd

By Travis Lundy

  • The HSCEI is well-known and well-followed but sees less passive tracking than you might expect. Quiddity teammember Janaghan had expected up to two ADDs and two DELETEs.
  • We got one ADD and one DELETE instead as SenseTime Group (20 HK) was “saved” from deletion by a FFW/FAF increase. 
  • Relatively smaller flows here at 3% one-way with the big flows on the name changes.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: BYD Electronics, Tencent and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • HSI June 2024 Rebal – BYD Electronics (285) ADDed, Cogard Svcs (6098) DELETEd, and Capping Flows
  • A Few Generative AI Takeaways From C1Q24 Earnings


HSI June 2024 Rebal – BYD Electronics (285) ADDed, Cogard Svcs (6098) DELETEd, and Capping Flows

By Travis Lundy

  • The Hang Seng Index benchmark has been expected to see an increase in names and flows to Healthcare. We have only one ADD (IT/tech) and one DELETE.
  • But the headlined DELETE candidate in the most recent Quiddity Leaderboard was chosen to be deleted. And the ADD one of our top two.
  • Flows are somewhat restrained at capping flows, small name change flows, and then a few FFW/FAF changes to be about 1.9% one-way flows in total.

A Few Generative AI Takeaways From C1Q24 Earnings

By Eric Wen

  • The key takeaway from this earning season on the topic of generative AI (GAI) is that in-house generated content has the greatest potential for cost savings;
  • Taking a step further, mid-sized video platforms can also use AI to skip the curator layer, similar to Pinduoduo using algorithm to bypass small merchants to connect directly to factories;
  • We also notice that general media platforms with ample advertising inventories tend to perform better with AI’s help, which is why ads of Tencent’s advertising performed better than Baidu’s.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: China Merchants Expressway Net, JD.com , Alibaba Group Holding , APT Medical , Shinva Medical Instrument A, Shenyang Xingqi Pharmaceutical, Eoflow, ESR Group , Li Auto , Yichang HEC Changjiang Pharma and more

By | Daily Briefs, Most Read

In today’s briefing:

  • CSI300 Index Rebalance Preview: Bounce in the Potential Deletes Could Be Short Lived
  • HSTECH Index Rebalance Preview: Round-Trip Trade of US$2.4bn in June
  • Alibaba (9988 HK): Dual Primary Listing & Potential Southbound Flows
  • CSI500 Index Rebalance Preview: Potential Adds Rally and Outperform the Potential Deletes
  • CSI Medical Service Index Rebalance Preview: Repeat of the December Rebal Could See Big Gains
  • ChiNext/​​​ChiNext50 Index Rebalance Preview: Outperformance Continues
  • Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps
  • (Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market
  • HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way
  • Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid


CSI300 Index Rebalance Preview: Bounce in the Potential Deletes Could Be Short Lived

By Brian Freitas

  • The review period for the June rebalance is complete and we expect 11 changes to the Shanghai Shenzhen CSI 300 Inde (SHSZ300 INDEX)
  • We estimate one-way turnover of 1.4% at the rebalance leading to a one-way trade of CNY 8.82bn (US$1.22bn). There are a lot of stocks with multiple days ADV to trade.
  • The potential deletes have bounced off their lows as the market has recovered. But the potential passive selling could see them underperform over the next month.

HSTECH Index Rebalance Preview: Round-Trip Trade of US$2.4bn in June

By Brian Freitas


Alibaba (9988 HK): Dual Primary Listing & Potential Southbound Flows

By Brian Freitas

  • Along with its fiscal 2024 results, Alibaba (9988 HK) announced that they were preparing for their primary listing in Hong Kong and the conversion was expected to complete by August.
  • If the conversion is completed by the end of August, Alibaba (9988 HK) could be added to Southbound Stock Connect in September and that could bring in significant flows.
  • We do not forecast any passive inflows due to the change with Alibaba Group Holding (9988 HK) capped at 8% of the HSI, HSCEI and HSTECH indices.

CSI500 Index Rebalance Preview: Potential Adds Rally and Outperform the Potential Deletes

By Brian Freitas

  • With the review period now complete, we forecast 50 changes (the maximum permitted) for the CSI Smallcap 500 Index – Shang (SH000905 INDEX) at the close on 14 June.
  • We estimate a one-way turnover of 9.3% at the rebalance resulting in a one-way trade of CNY10.88bn (US$1.5bn). The Industrials and Information Technology sectors gain at the expense of Materials.
  • The potential adds have outperformed the potential deletes by 8% over the last 3 months. There could be further outperformance over the next few weeks.

CSI Medical Service Index Rebalance Preview: Repeat of the December Rebal Could See Big Gains

By Brian Freitas

  • The review period ended on 30 April, there are just over 2 weeks to announcement of the changes, and implementation will be done at the close on 14 June.
  • We forecast 5 potential changes for the index in June where there could be buying of 1.6-2.6x ADV on the adds and selling of 0.7-2.6x ADV on the deletes.
  • At the December 2023 rebalance, the adds outperformed the deletes in the weeks prior to announcement of the changes and then spiked post-announcement. Repeat this time?

ChiNext/​​​ChiNext50 Index Rebalance Preview: Outperformance Continues

By Brian Freitas

  • With the review period now complete, we forecast 7 changes for the ChiNext Index (SZ399006 INDEX) and 5 changes for the ChiNext 50 Index in June.
  • There are 4 stocks that could be added to both indices while some stocks will also have same way flows from CSI Smallcap 500 Index (SH000905 INDEX) trackers.
  • The potential adds have outperformed the potential deletes over the last 6 months. There has been a big move higher in the potential adds over the last few weeks.

Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps

By Douglas Kim

  • In this insight, we discuss the additional financing requirements, changed shareholding structure, and the next steps for Eoflow. 
  • Eoflow is one of the best performing stocks in the Korean stock market in the past one month as its shares have soared 249% in this period.
  • The details of the oral argument (Insulet vs Eoflow) at the U.S. Appellate Court suggest that the U.S. Appellate Court may rule in favor of Eoflow.

(Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market

By David Blennerhassett


HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way

By Travis Lundy

  • The Hang Seng Tech Index is more widely-followed than many think, and it is reasonably concentrated, so outperformance and underperformance by big names means capping and re-capping.
  • This time, those flows are worth about 8% of the index in terms of one-way flows. Meituan, Xiaomi, JD.com, Tencent and Kuaishou Tech DOWN. Li Auto back up. 
  • Those who have pre-positioned on the big buy have recently gotten hurt. There are some FAF changes which are less predictable and may be interesting.

Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid

By David Blennerhassett

  • A “Privatisation via a Merger by Absorption” is nothing new in Hong Kong. But the Offer consideration for Yichang HEC (1558 HK)‘s minorities is in unlisted scrip – that’s new. 
  • The Offeror holds 51.41% in Yichang HEC. Founder Guo Meilan and her son Zhang Yushuai control 62.12% of the Offeror. Yichang HEC shareholders are being offered 0.263614 “Offeror H shares”.
  • These consideration shares are unlisted. An independent valuer backs out an implied scrip value of HK$18.12-HK$20.60/share. This is a super complicated, overwrought deal. With numerous unknowns. I’d vote this down. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Financials: ESR Group , Brightcom Group, KakaoBank and more

By | Daily Briefs, Financials

In today’s briefing:

  • (Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market
  • Indian Forensic Playbook: Guidelines to Identify and Avoid Storified Stocks
  • EM Digital Banks – We Turn Positive on KakaoBank and Inter, Cautious on Nubank and Neutral on PAN


(Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market

By David Blennerhassett


Indian Forensic Playbook: Guidelines to Identify and Avoid Storified Stocks

By Nimish Maheshwari

  • Indian SMEs are new hot investment avenues selling stories to investors which might end to a case of pump and dump.
  • SEBI in last few months have identified such cases in SMEs and microcaps.
  • We delved into key guidelines on Indian Forensics to Identify and Avoid Storified Stocks

EM Digital Banks – We Turn Positive on KakaoBank and Inter, Cautious on Nubank and Neutral on PAN

By Victor Galliano

  • We turn positive on KakaoBank, for its increasingly secure competitive positioning in Korea, its attractive digital efficiency ratio, its low customer acquisition cost and for its high activity rate
  • We switch our buy rating from PAN to Inter as the latter has improved operationally, it is sound on capital and attractive on valuations
  • Nubank is executing well, but we remain cautious on Nubank shares as we continue to see potential capital constraints as a key risk, along with its stretched valuations

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Zen Technologies, Japan Post Holdings and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Zen Technologies: Building a Strong Moat in Indian Defence Theme
  • Last Week in Event SPACE: Japan Post, Great Eastern, Malaysia Airports, L’Occitane


Zen Technologies: Building a Strong Moat in Indian Defence Theme

By Sudarshan Bhandari

  • Zen Technologies (ZEN IN) expands product range to drones, anti-drone systems, and medical simulators, enhancing opportunities beyond government contracts.
  • Strong order book of Rs 1,401 crore, significant R&D investment, and government support for indigenous defence manufacturing drive growth.
  • Zen Technologies (ZEN IN) diversified product portfolio and strategic government support position it well for significant growth in the defence and simulation markets.

Last Week in Event SPACE: Japan Post, Great Eastern, Malaysia Airports, L’Occitane

By David Blennerhassett


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Yichang HEC Changjiang Pharma, Basilea Pharmaceutica Ag and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid
  • Basilea Pharmaceutica – Cresemba milestone payments continue to roll in


Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid

By David Blennerhassett

  • A “Privatisation via a Merger by Absorption” is nothing new in Hong Kong. But the Offer consideration for Yichang HEC (1558 HK)‘s minorities is in unlisted scrip – that’s new. 
  • The Offeror holds 51.41% in Yichang HEC. Founder Guo Meilan and her son Zhang Yushuai control 62.12% of the Offeror. Yichang HEC shareholders are being offered 0.263614 “Offeror H shares”.
  • These consideration shares are unlisted. An independent valuer backs out an implied scrip value of HK$18.12-HK$20.60/share. This is a super complicated, overwrought deal. With numerous unknowns. I’d vote this down. 

Basilea Pharmaceutica – Cresemba milestone payments continue to roll in

By Edison Investment Research

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the first of two Phase III trials expected to initiate in mid-2024. The company also made positive regulatory and operational strides with its lead antibiotic asset, Zevtera (following FDA approval in April 2024), and we eagerly await the announcement of a potential US commercial partner.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars